Nephros IncNEPH

Nephros Inc. is a micro-cap filtration company that sells point-of-use water filters small enough to catch bacteria at 0.1 micron and ultrafilters fine enough to stop particles at 0.005 micron-useful gear if you run a hospital, dialysis unit, or a commercial kitchen that would rather not serve guests a side of Legionella with their latte. The company’s product pages promise infection-control solutions, on-time delivery, and a customer-service line that never sleeps, complete with reassuring quotes like ‘there is always someone at Nephros available to offer assistance.’ What the pages do not promise is a cash pile that grows faster than the inventory sitting in the warehouse. (source: Water Filtration Products | Point-of-Use Filters | Nephros, https://www.nephros.com/products/; How Nephros Water Filtration Can Help | Nephros, https://www.nephros.com/services/)

The latest SEC filings show a company that is technically profitable-$140,000 net income in the quarter ended 31 March 2026-but the operating cash flow was a negative $1.7 million, meaning the business is generating paper profits while haemorrhaging real dollars. Revenue for the quarter was $5.2 million, up a rounding error from $5.1 million in the same quarter last year, which is the kind of growth that makes you wonder whether the sales team is selling more filters or simply changing the invoice date. The board’s ethics code is free to download, but the 15 June 2026 8-K reveals the board waived its own code for a related-party transaction, a manoeuvre that usually accompanies a business that has run out of shareholder goodwill but is still flush with family connections. (source: Nephros Inc., 10-Q for quarter ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1196298/000149315226021701/form10-q.htm; Nephros Inc., 8-K dated 2026-06-15, https://www.sec.gov/Archives/edgar/data/1196298/000149315226028539/form8-k.htm)

The balance sheet tells the clearer story: $13.8 million in assets against $3.1 million in liabilities, with cash and equivalents at $4.0 million and inventory at $3.6 million. The inventory build of $398,000 in the quarter suggests the company is either confidently stocking up for a boom or quietly praying the filters turn into cash before the warehouse rent comes due. The diluted share count sits at 11.0 million shares, so every dollar of net income is spread thin across a float that would struggle to fill a single dialysis bay. Earnings per share came in at one cent, which is a rounding error even for a dialysis patient counting drops. (source: Nephros Inc., 10-Q for quarter ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1196298/000149315226021701/form10-q.htm)

The company’s official education pages promise pathogen and outbreak support, which sounds urgent until you realise the page is titled ‘resources/education’ and the most recent post appears to date from a marketing cycle that has since moved on. The product images show sterile white filters against clinical backgrounds, a visual cue that suggests sterility more than scalability. If the filters are the hero, the story right now is a supporting character waiting for a sequel that may never green-light. (source: Water Filtration Resources & Education | Nephros, https://www.nephros.com/resources/education/?paged=1&em_resources_topic=outbreak-support&orderby=title)

The SEC filings do not disclose any formal guidance, and the company’s website does not offer forward-looking statements beyond the usual boilerplate about ‘reliable partners’ and ‘prompt customer service.’ The operating cash burn, together with the inventory build and the board’s ethics waiver, leaves the equity story dependent on two unproven propositions: first, that the filters will sell through faster than they are built; second, that the board’s ethics waivers are exceptions rather than the rule. Until either proposition is evidenced in the cash-flow line, the stock is a bet on belief rather than fundamentals. (source: Nephros Inc., 10-Q for quarter ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1196298/000149315226021701/form10-q.htm)